BRUSSELS (Reuters) – The European Union’s executive said on Wednesday it had agreed to buy a limited supply of the COVID-19 medicine remdesivir from U.S. drugmaker Gilead (GILD.O) to address the short-term needs of European patients, and hoped to be able to order more later.
The anti-viral is the only drug so far authorised in the EU to treat patients with severe symptoms of COVID-19, but nearly all available supplies have already been bought by the United States.
The EU Commission has agreed to pay 63 million euros ($74 million) to buy enough doses to treat about 30,000 patients, it said in a statement.
Source: Reuters
FINANCED BY
This project was funded in part through a U.S. Embassy grant. The opinions, findings, and conclusions or recommendations expressed herein are those of the implementers/authors and do not necessarily reflect those of the U.S. Government.
PARTNERS
